GEN Exclusives

More »

GEN News Highlights

More »
Oct 1, 2007

Argenta to Aid CellCentric in Epigenetic Research

  • Argenta Discovery entered into a fee-for-service collaboration with CellCentric. Under the terms of the agreement, scientists from the two companies will exploit Argenta’s expertise to discover inhibitors for two potential epigenetic-related therapeutic targets.

    “Their decision to work with us is based on our contract drug discovery team’s acknowledged expertise in hit identification and assay development,” notes Christopher Ashton, Argenta’s chief executive.

    Will West, CEO of CellCentric adds that Argenta’s know-how in hit identification, assay development, and screening will help advance the company’s knowledge and expertise in epigenetic research.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?